Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.50 |
| ▸ | CTSK | P43235 | 10/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10796108 | 0.93 | CTSS (0.50) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL4452913 | 0.93 | CTSS (0.50) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL10796111 | 0.93 | CTSS (0.50) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL12396372 | 0.88 | CTSS (0.47) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL25886335 | 0.88 | CTSS (0.47) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL25886340 | 0.87 | CTSK (0.49) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL13402318 | 0.87 | CTSK (0.49) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL28140915 | 0.87 | CTSK (0.49) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL14923491 | 0.86 | CTSS (0.49) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL580779 | 0.86 | PPARA (0.53) | CTSSCTSKCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901353-B2 | Polyimide precursor, polyimide, and liquid crystal aligning agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-7691558-B2 | Photosensitive composition, compound for use in the photosensitive composition and pattern forming method using the photosensitive composition | FUJIFILM CORPORATION (JP) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | PUF60, F13A1, F12 | CTSS 4745/4885CTSK 4427/4885CTSL 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.